HK1209673A1 - Using modulators of ccr5 for treating cancer ccr5 - Google Patents
Using modulators of ccr5 for treating cancer ccr5Info
- Publication number
- HK1209673A1 HK1209673A1 HK15110378.4A HK15110378A HK1209673A1 HK 1209673 A1 HK1209673 A1 HK 1209673A1 HK 15110378 A HK15110378 A HK 15110378A HK 1209673 A1 HK1209673 A1 HK 1209673A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- ccr5
- modulators
- treating cancer
- cancer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, ***e
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261646593P | 2012-05-14 | 2012-05-14 | |
US201261646586P | 2012-05-14 | 2012-05-14 | |
PCT/US2013/040917 WO2013173312A1 (en) | 2012-05-14 | 2013-05-14 | Using modulators of ccr5 for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209673A1 true HK1209673A1 (en) | 2016-04-08 |
Family
ID=49549081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15110378.4A HK1209673A1 (en) | 2012-05-14 | 2015-10-22 | Using modulators of ccr5 for treating cancer ccr5 |
Country Status (8)
Country | Link |
---|---|
US (4) | US9453836B2 (xx) |
EP (1) | EP2861302A4 (xx) |
JP (2) | JP6518585B2 (xx) |
CN (1) | CN104853806A (xx) |
AU (4) | AU2013262977A1 (xx) |
CA (1) | CA2873743C (xx) |
HK (1) | HK1209673A1 (xx) |
WO (1) | WO2013173312A1 (xx) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2873743C (en) * | 2012-05-14 | 2022-12-06 | Prostagene, Llc | Using modulators of ccr5 for treating cancer |
WO2016066634A2 (en) * | 2014-10-27 | 2016-05-06 | Ruprecht-Karls-Universität Heidelberg | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
US20180303830A1 (en) * | 2015-06-22 | 2018-10-25 | Thomas Jefferson University | Cancers expressing ccr5 and methods of treatment of same |
WO2017058896A1 (en) * | 2015-09-28 | 2017-04-06 | Sanford Burnham Prebys Medical Discovery Institute | Targets for treatment of hepatocellular carcinoma cancer and methods related thereto |
WO2017201043A1 (en) * | 2016-05-16 | 2017-11-23 | Concert Pharmaceuticals, Inc. | Combination therapy for treating cancer |
CA3101556A1 (en) * | 2018-05-28 | 2019-12-05 | ORION Biotechnology Switzerland Sarl | Ccr5 inhibitor for use in treating cancer |
KR20220127859A (ko) * | 2020-01-13 | 2022-09-20 | 사이토딘 인크. | Ccr5 양성 전이성 암 치료를 위한 ccr5 결합제 |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
US11402391B2 (en) | 2020-12-21 | 2022-08-02 | Incelldx, Inc. | Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist |
CN114106207B (zh) * | 2022-01-24 | 2022-04-26 | 诺未科技(北京)有限公司 | Ccl5的用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
ATE199553T1 (de) | 1994-09-29 | 2001-03-15 | Novartis Erfind Verwalt Gmbh | Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung |
US20040151719A1 (en) | 1995-06-06 | 2004-08-05 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor (CCR5) HDGNR10 |
GB9520822D0 (en) | 1995-10-11 | 1995-12-13 | Wellcome Found | Therapeutically active compounds |
PT874846E (pt) | 1995-11-01 | 2003-08-29 | Novartis Ag | Derivados de purina e processos para a sua preparacao |
CH690773A5 (de) | 1996-02-01 | 2001-01-15 | Novartis Ag | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. |
AU1794697A (en) | 1996-03-06 | 1997-09-22 | Novartis Ag | 7-alkyl-pyrrolo{2,3-d}pyrimidines |
AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
ES2186908T3 (es) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | Compuestos heterociciclos condensados como inhibidores de pproteina-tirosina-quinasas. |
TR199900048T2 (xx) | 1996-07-13 | 1999-04-21 | Glaxo Group Limited | Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler |
GB9800569D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
GB9800575D0 (en) | 1998-01-12 | 1998-03-11 | Glaxo Group Ltd | Heterocyclic compounds |
PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
RU2312860C2 (ru) | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Циклические ингибиторы протеинтирозинкиназ |
US7825121B2 (en) * | 1999-05-04 | 2010-11-02 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
US6689765B2 (en) * | 1999-05-04 | 2004-02-10 | Schering Corporation | Piperazine derivatives useful as CCR5 antagonists |
MXPA02007730A (es) | 2000-02-09 | 2002-10-11 | Human Genome Sciences Inc | Receptor de quimiocina de proteina g humana (ccr5) hdgnr10. |
US6667314B2 (en) | 2000-05-26 | 2003-12-23 | Pfizer, Inc. | Tropane derivatives useful in therapy |
JP2005503116A (ja) * | 2001-02-09 | 2005-02-03 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒトgタンパク質ケモカインレセプター(ccr5)hdgnr10 |
US20020182624A1 (en) | 2001-02-28 | 2002-12-05 | Eos Biotechnology, Inc. | Chemokine receptors and disease |
GB0108876D0 (en) | 2001-04-09 | 2001-05-30 | Novartis Ag | Organic Compounds |
EP1570860A4 (en) * | 2002-12-13 | 2009-06-03 | Ono Pharmaceutical Co | ANTAGONIST AND AGONIST BINDING TO A STRONG BINDING SITE OF THE CHEMOKINE RECEPTOR |
US20070270429A1 (en) * | 2003-05-06 | 2007-11-22 | Shiro Shibayama | Function Inhibitor of Effector Cell |
EP1831210A1 (en) * | 2004-12-23 | 2007-09-12 | Pfizer Limited | 8-aza-bicyclo[3.2.1]octane derivatives with an activity on chemokine ccr5 receptors |
WO2006121991A2 (en) * | 2005-05-06 | 2006-11-16 | Diadexus, Inc. | Compositions and methods for detection, prognosis and treatment of breast cancer |
US7872027B2 (en) | 2006-02-17 | 2011-01-18 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Low molecular weight Myc-max inhibitors |
US20080118437A1 (en) | 2006-03-01 | 2008-05-22 | Regents Of The University Of Michigan | Diagnosis and treatment O prostate cancer |
EP1995246A4 (en) * | 2006-03-10 | 2010-11-17 | Ono Pharmaceutical Co | NITROGENATED HETEROCYCLIC DERIVATIVE AND MEDICAMENT WITH DERIVATIVE ACTIVE SUBSTANCE |
WO2008109154A1 (en) * | 2007-03-08 | 2008-09-12 | Altiris Therapeutics, Inc. | Chemokine receptor modulators |
JOP20090061B1 (ar) | 2008-02-11 | 2021-08-17 | Ferring Int Center Sa | طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH |
WO2010056337A2 (en) | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
BR112013023050A8 (pt) * | 2011-03-09 | 2018-09-25 | G Pestell Richard | antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal |
CA2873743C (en) | 2012-05-14 | 2022-12-06 | Prostagene, Llc | Using modulators of ccr5 for treating cancer |
-
2013
- 2013-05-14 CA CA2873743A patent/CA2873743C/en active Active
- 2013-05-14 AU AU2013262977A patent/AU2013262977A1/en not_active Abandoned
- 2013-05-14 EP EP13790117.9A patent/EP2861302A4/en not_active Withdrawn
- 2013-05-14 JP JP2015512749A patent/JP6518585B2/ja active Active
- 2013-05-14 CN CN201380037638.6A patent/CN104853806A/zh active Pending
- 2013-05-14 WO PCT/US2013/040917 patent/WO2013173312A1/en active Application Filing
- 2013-05-14 US US13/893,791 patent/US9453836B2/en active Active
-
2015
- 2015-10-22 HK HK15110378.4A patent/HK1209673A1/xx unknown
-
2016
- 2016-09-23 US US15/275,050 patent/US20170231991A1/en not_active Abandoned
-
2018
- 2018-03-02 AU AU2018201516A patent/AU2018201516A1/en not_active Abandoned
-
2019
- 2019-03-25 US US16/363,981 patent/US11633397B2/en active Active
- 2019-04-22 JP JP2019080669A patent/JP7003083B2/ja active Active
-
2020
- 2020-01-06 AU AU2020200083A patent/AU2020200083A1/en not_active Abandoned
-
2022
- 2022-03-23 AU AU2022201992A patent/AU2022201992A1/en active Pending
-
2023
- 2023-03-03 US US18/178,037 patent/US20230364085A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2019168459A (ja) | 2019-10-03 |
CA2873743A1 (en) | 2013-11-21 |
US20170231991A1 (en) | 2017-08-17 |
AU2018201516A1 (en) | 2018-03-22 |
AU2013262977A1 (en) | 2015-01-22 |
JP7003083B2 (ja) | 2022-02-04 |
AU2020200083A1 (en) | 2020-01-30 |
US20230364085A1 (en) | 2023-11-16 |
AU2022201992A1 (en) | 2022-04-14 |
EP2861302A4 (en) | 2016-08-24 |
JP2015518957A (ja) | 2015-07-06 |
CN104853806A (zh) | 2015-08-19 |
US20130303512A1 (en) | 2013-11-14 |
CA2873743C (en) | 2022-12-06 |
WO2013173312A1 (en) | 2013-11-21 |
US11633397B2 (en) | 2023-04-25 |
US20190314371A1 (en) | 2019-10-17 |
JP6518585B2 (ja) | 2019-05-22 |
EP2861302A1 (en) | 2015-04-22 |
US9453836B2 (en) | 2016-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL288181A (en) | Cancer treatment methods | |
IL237791A0 (en) | A method for treating cancer | |
HK1209673A1 (en) | Using modulators of ccr5 for treating cancer ccr5 | |
PL2818482T3 (pl) | Kompozycja farmaceutyczna do leczenia nowotworu | |
HUE045461T2 (hu) | Gyógyászati készítmény rák kezelésére | |
SG11201503893RA (en) | Method of treating cancer | |
HK1214128A1 (zh) | 癌症的治療 | |
HK1205254A1 (en) | Methods of treatment of cancer | |
EP2895206A4 (en) | METHOD FOR TREATING CARCINOMA | |
GB201217892D0 (en) | Treatment of cancer | |
HK1204956A1 (en) | Treatment of cancer | |
SI2892925T1 (sl) | Kombinacijsko zdravljenje raka | |
EP2897607A4 (en) | BETA-HYDROLASE INHIBITORS FOR THE TREATMENT OF CANCER | |
IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
FI3473276T3 (fi) | Tekniikoita paiseiden hoitoon | |
GB201217890D0 (en) | Treatment of cancer | |
GB201208296D0 (en) | Treatment of cancer | |
GB201222949D0 (en) | Combination Treatment of Cancer | |
GB201222950D0 (en) | Combination treatment of cancer |